Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo

Autor: B. Onteniente, M. Lhuillier, Catherine Widmann, Marc Borsotto, Catherine Heurteaux, M Lazdunski, C. Gandin, Frédéric Brau
Přispěvatelé: Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Institut des cellules souches pour le traitement et l'étude des maladies monogéniques (I-STEM), Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Généthon, Université Nice Sophia Antipolis (1965 - 2019) (UNS)
Rok vydání: 2010
Předmět:
Zdroj: Oncogene
Oncogene, Nature Publishing Group, 2010, 58 (7), pp.987-1001. ⟨10.1016/j.neuropharm.2010.01.001⟩
Oncogene, 2010, 58 (7), pp.987-1001. ⟨10.1016/j.neuropharm.2010.01.001⟩
ISSN: 0028-3908
0950-9232
1476-5594
Popis: International audience; Although stroke remains a leading cause of death and adult disability, numerous recent failures in clinical stroke trials have led to some pessimism in the field. Interestingly, NeuroAid (MLC601), a traditional medicine, particularly used in China, South East Asia and Middle East has been reported to have beneficial effects in patients, particularly in post-stroke complications. Here, we demonstrate in a rodent model of focal ischemia that NeuroAid II (MLC901) pre- and post-treatments up to 3 h after stroke improve survival, protect the brain from the ischemic injury and drastically decrease functional deficits. MLC601 and MLC901 also prevent neuronal death in an in vitro model of excitotoxicity using primary cultures of cortical neurons exposed to glutamate. In addition, MLC601/MLC901 treatments were shown to induce neurogenesis in rodent and human cells, promote cell proliferation as well as neurite outgrowth and stimulate the development of a dense axonal and dendritic network. MLC601 and MLC901 clearly represent a very interesting strategy for stroke treatment at different stages of the disease.
Databáze: OpenAIRE